Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 442-453

  Cras, Audrey ^a,b,c   Politis, Béatrice ^a,b   Balitrand, Nicole ^a,b,c   Darsin Bettinger, Diane ^a,b,c   Boelle, Pierre Yves ^a,d,e   Cassinat, Bruno ^a,b,c   Toubert, Marie Elisabeth ^c   Chomienne, Christine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTRETINOIN; MESSENGER RNA; RADIOACTIVE IODINE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; RETINOID X RECEPTOR; RETINOID X RECEPTOR GAMMA; SYNAPTOTAGMIN I;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CANCER SURGERY; CELL GROWTH; CELL TRANSPORT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEACETYLATION; DIFFERENTIATED THYROID CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; RECEPTOR GENE; RETINOIC ACID RECEPTOR ALPHA GENE; RETINOIC ACID RECEPTOR GENE; RETINOID X RECEPTOR GENE; SIGNAL TRANSDUCTION; THYROID CANCER; TRANSACTIVATION; TREATMENT DURATION; TUMOR DIFFERENTIATION;

ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; E1A-ASSOCIATED P300 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NF-KAPPA B; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTOR GAMMA; TETRAHYDRONAPHTHALENES; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; TRETINOIN;

EID: 84856007949     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0510     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 2005;46:1473-80.
3. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
4. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport systemin thyroid cancer cell metabolism. Eur J Endocrinol 1999;141:443-57.
5. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228-34. (Pubitemid 30646949)
6. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A, et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ 1998;9: 97-103. (Pubitemid 28049532)
7. Pasca di Magliano M, Di Lauro R, Zannini M. Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci U S A 2000;97:13144-9.
8. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D, et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998;76:368-76. (Pubitemid 28282936)
9. Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ, Jozan S. Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and Western blot study. Histopathology 1998;33:337-43. (Pubitemid 28508883)
10. Carpentier AF, Leonard N, Lacombe J, Zassadowski F, Padua RA, Degos L, et al. Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. Anticancer Res 1999;19:3189-92. (Pubitemid 30042608)
11. Chomienne C, Balitrand N, Ballerini P, Castaigne S, de The H, Degos L. All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J Clin Invest 1991;88:2150-4.
12. Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol 2004;150:547-56. (Pubitemid 38584707)
13. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.
14. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-6.
15. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-74. (Pubitemid 28215434)
16. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J NuclMedMol Imaging 2002;29:775-82.
17. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 2009;56:105-12.
18. Short SC, Suovuori A, Cook G, Vivian G, Harmer C. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 2004;16: 569-74. (Pubitemid 39517666)
19. Liu YY, Stokkel MP, Morreau HA, Pereira AM, Romijn JA, Smit JW. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008;68:605-9. (Pubitemid 351388717)
20. Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-31.
21. Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulie A, Toubert ME, et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007;26:4018-24. (Pubitemid 46884303)
22. Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990;118:48-63.
23. Delva L, Bastie JN, Rochette-Egly C, Kraiba R, Balitrand N, Despouy G, et al. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol Cell Biol 1999;19:7158-67. (Pubitemid 29441896)
24. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptorselective ligands. N Engl J Med 1999;340:1075-9. (Pubitemid 29162512)
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
26. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10:393-406.
27. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 2004;555:81-96. (Pubitemid 39359177)
28. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
29. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006;25:6868-86. (Pubitemid 44657857)
30. Alotaibi H, Yaman E, Salvatore D, Di Dato V, Telkoparan P, Di Lauro R, et al. Intronic elements in the Na+/I- symporter gene (NIS) interact with retinoic acid receptors and mediate initiation of transcription. Nucleic Acids Res 2010;38:3172-85.
31. Ohashi E, Kogai T, Kagechika H, Brent GA. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res 2009;69:3443-50.
32. Takiyama Y, Miyokawa N, Sugawara A, Kato S, Ito K, Sato K, et al. Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5851-61. (Pubitemid 39518481)
33. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase IIIII trial results. J Clin Oncol 2001;19:2456-71. (Pubitemid 32391217)
34. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003;21:999-1006. (Pubitemid 46594127)
35. Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, et al. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol 2006;24:4848-54. (Pubitemid 46630911)
36. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40.
37. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 2007;13:1794-1800.
38. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004;89:272-80. (Pubitemid 38183893)
39. Hoffmann S, Rockenstein A, Ramaswamy A, Celik I, Wunderlich A, Lingelbach S, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 2007;264:74-81. (Pubitemid 46097303)
40. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006;94:654-60. (Pubitemid 43361896)
41. Wang D, Richmond A. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 2001;276:3650-9.
42. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002;21:8178-85. (Pubitemid 35454421)
43. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004;279:24015-23.
44. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 2004;279:54610-9. (Pubitemid 40053204)
45. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997;15:1987-94.
46. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl) retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res 2005;65:9555-65. (Pubitemid 41508026)
47. Hoo RL, Chan KY, Leung FK, Lee LT, Leung PC, Chow BK. Involvement of NF-kappaB subunit p65 and retinoic acid receptors, RARalpha andRXRalpha, in transcriptional regulation of the humanGnRH II gene. FEBS J 2007;274:2695-706. (Pubitemid 46800540)
48. Na SY, Kang BY, Chung SW, Han SJ, Ma X, Trinchieri G, et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J Biol Chem 1999;274:7674-80.